HepG2 exosomes coated luteolin nanoparticles remodeling hepatic stellate cells and combination with sorafenib for the treatment of hepatocellular carcinoma

被引:1
作者
Ye, Shengjie [1 ,2 ]
Pan, Xier [1 ,2 ]
Zou, Linghui [1 ,2 ]
Ni, Shuting [2 ]
Zhang, Lei [3 ]
Hong, Yanlong [3 ]
Hu, Kaili [1 ,2 ]
机构
[1] Shanghai Univ Tradit Chinese Med, Sch Pharm, Shanghai 201203, Peoples R China
[2] Shanghai Univ Tradit Chinese Med, Inst Interdisciplinary Integrat Med Res, Shanghai Frontiers Sci Ctr TCM Chem Biol, Shanghai 201203, Peoples R China
[3] Shanghai Univ Tradit Chinese Med, Shanghai Innovat Ctr, TCM Hlth Serv, Shanghai 201203, Peoples R China
关键词
Biomimetic nanoparticles; Hepatic stellate cells; Luteolin; Sorafenib; Hepatocellular carcinoma; EPITHELIAL-MESENCHYMAL TRANSITION; EXTRACELLULAR VESICLES; RAF/MEK/ERK PATHWAY; PLUS SORAFENIB; LIVER-CANCER; DELIVERY; APOPTOSIS; THERAPY; TUMOR; PROGRESSION;
D O I
10.1186/s12645-024-00253-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundHepatocellular carcinoma (HCC) is a common malignant tumor with high mortality and recurrence rate. The efficacy of the first-line drug sorafenib is impeded by drug resistance, which is closely related to activated hepatic stellate cells (HSCs). The natural product luteolin is good at alleviating the activation of HSC. However, its clinical application is limited to poor solubility, bioavailability and lacking of HSCs targeting effects. This study aims to construct luteolin-loaded biomimetic nanoparticles based on HepG2 exosomes for targeting HSCs and enhancing the therapeutic effects of sorafenib on HCC.MethodsThe HepG2 exosomes extracted were identified by size distribution, Zeta potential and characteristic proteins. Luteolin-loaded polylactic acid-glycolic acid (PLGA) nanoparticles (Lut-NPs) were prepared and wrapped by HepG2 exosomes to form biomimetic nanoparticles (Exo-Lut-NPs). A HepG2 cell sorafenib-resistant model induced by LX2 cell conditioned medium (CM) was established to evaluate the effects of Exo-Lut-NPs on reversing sorafenib-resistant in vitro. And the combined therapeutic effects of Exo-Lut-NPs with sorafenib were evaluated on a HepG2/LX2 subcutaneous xenograft tumor model in vivo.ResultsThe particle size, drug loading capacity and encapsulation efficiency of Exo-Lut-NPs were 165 +/- 10 nm, 2.6 +/- 0.2% and 56.9 +/- 4.3%, respectively. The in vitro HepG2 sorafenib-resistant model was induced by the CM of LX2 cells, and the results showed that Exo-Lut-NPs partially reversed the sorafenib resistance of HepG2 cells by affecting the CM of LX2 cells. The combined therapy of Exo-Lut-NPs with sorafenib markedly suppressed tumor growth in a HepG2/LX2 subcutaneous xenograft tumor model.ConclusionsThis study suggests that the Exo-Lut-NP is a novel and promising biomimetic delivery system which can combine with sorafenib for HCC therapy.
引用
收藏
页数:22
相关论文
共 94 条
  • [71] Exosomes derived from Vδ2-T cells control Epstein-Barr virus-associated tumors and induce T cell antitumor immunity
    Wang, Xiwei
    Xiang, Zheng
    Liu, Yinping
    Huang, Chunyu
    Pei, Yujun
    Wang, Xia
    Zhi, Hui
    Wong, Wilfred Hing-Sang
    Wei, Haiming
    Ng, Irene Oi-Lin
    Lee, Pamela Pui-Wah
    Chan, Godfrey Chi-Fung
    Lau, Yu-Lung
    Tu, Wenwei
    [J]. SCIENCE TRANSLATIONAL MEDICINE, 2020, 12 (563)
  • [72] A Rapid and Facile Separation-Detection Integrated Strategy for Exosome Profiling Based on Boronic Acid-Directed Coupling Immunoaffinity
    Wang, Yi-Ting
    Cai, Ming-Di
    Sun, Li-Li
    Hua, Rui-Nian
    [J]. ANALYTICAL CHEMISTRY, 2021, 93 (48) : 16059 - 16067
  • [73] Combinatorial immunotherapy of sorafenib and blockade of programmed death-ligand 1 induces effective natural killer cell responses against hepatocellular carcinoma
    Wang, Yun
    Li, Hongxia
    Liang, Qi
    Liu, Bin
    Mei, Xiaqi
    Ma, Yingji
    [J]. TUMOR BIOLOGY, 2015, 36 (03) : 1561 - 1566
  • [74] Sorafenib-irinotecan sequential therapy augmented the anti-tumor efficacy of monotherapy in hepatocellular carcinoma cells HepG2
    Wang, Z.
    Zhao, Z.
    Wu, T.
    Song, L.
    Zhang, Y.
    [J]. NEOPLASMA, 2015, 62 (02) : 172 - 179
  • [75] BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
    Wilhelm, SM
    Carter, C
    Tang, LY
    Wilkie, D
    McNabola, A
    Rong, H
    Chen, C
    Zhang, XM
    Vincent, P
    McHugh, M
    Cao, YC
    Shujath, J
    Gawlak, S
    Eveleigh, D
    Rowley, B
    Liu, L
    Adnane, L
    Lynch, M
    Auclair, D
    Taylor, I
    Gedrich, R
    Voznesensky, A
    Riedl, B
    Post, LE
    Bollag, G
    Trail, PA
    [J]. CANCER RESEARCH, 2004, 64 (19) : 7099 - 7109
  • [76] Standardization of sample collection, isolation and analysis methods in extracellular vesicle research
    Witwer, Kenneth W.
    Buzas, Edit I.
    Bemis, Lynne T.
    Bora, Adriana
    Lasser, Cecilia
    Lotvall, Jan
    Hoen, Esther N. Nolte-'t
    Piper, Melissa G.
    Sivaraman, Sarada
    Skog, Johan
    Thery, Clotilde
    Wauben, Marca H.
    Hochberg, Fred
    [J]. JOURNAL OF EXTRACELLULAR VESICLES, 2013, 2 (01)
  • [77] Preservation of small extracellular vesicles for functional analysis and therapeutic applications: a comparative evaluation of storage conditions
    Wu, Jun-Yong
    Li, Yong-Jiang
    Hu, Xiong-Bin
    Huang, Si
    Xiang, Da-Xiong
    [J]. DRUG DELIVERY, 2021, 28 (01) : 162 - 170
  • [78] Cancer statistics in China and United States, 2022: profiles, trends, and determinants
    Xia, Changfa
    Dong, Xuesi
    Li, He
    Cao, Maomao
    Sun, Dianqin
    He, Siyi
    Yang, Fan
    Yan, Xinxin
    Zhang, Shaoli
    Li, Ni
    Chen, Wanqing
    [J]. CHINESE MEDICAL JOURNAL, 2022, 135 (05) : 584 - 590
  • [79] The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinoma
    Xia, Shunjie
    Pan, Yu
    Liang, Yuelong
    Xu, Junjie
    Cai, Xiujun
    [J]. EBIOMEDICINE, 2020, 51
  • [80] Effects of the epigenetic drug MS-275 on the release and function of exosome-related immune molecules in hepatocellular carcinoma cells
    Xiao, Wenhua
    Dong, Weiwei
    Zhang, Caihong
    Saren, Gaowa
    Geng, Paili
    Zhao, Huixia
    Li, Quiwen
    Zhu, Jianhua
    Li, Guanghui
    Zhang, Shufang
    Ye, Ming
    [J]. EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2013, 18